Literature DB >> 11470997

Identification and functional characterization of eight CYP3A4 protein variants.

R Eiselt1, T L Domanski, A Zibat, R Mueller, E Presecan-Siedel, E Hustert, U M Zanger, J Brockmoller, H P Klenk, U A Meyer, K K Khan, Y A He, J R Halpert, L Wojnowski.   

Abstract

The genetic component of the inter-individual variability in CYP3A4 activity has been estimated to be between 60% and 90%, but the underlying genetic factors remain largely unknown. A study of 213 Middle and Western European DNA samples resulted in the identification of 18 new CYP3A4 variants, including eight protein variants. A total of 7.5% of the population studied was found to be heterozygous for one of these variants. In a bacterial heterologous expression system, two mutants, R130Q and P416L, did not result in detectable P450 holoprotein. One mutant, T363M, expressed at significantly lower levels than wild-type CYP3A4. G56D, V170I, D174H and M445T were not significantly different when compared with wild-type CYP3A4 in expression or steroid hydroxylase activity. L373F displayed a significantly altered testosterone metabolite profile and a four-fold increase in the Km value for 1'-OH midazolam formation. The results suggest a limited contribution of CYP3A4 protein variants to the inter-individual variability of CYP3A4 activity in Caucasians. Some variants may, however, play a role in the atypical response to drugs or altered sensitivity to carcinogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470997     DOI: 10.1097/00008571-200107000-00008

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  40 in total

1.  In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignacio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

Review 2.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

3.  CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

Authors:  C Balram; Qingyu Zhou; Yin Bun Cheung; Edmund J D Lee
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

4.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

5.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

6.  In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

Review 7.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

8.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

10.  Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

Authors:  Chin B Eap; Thierry Buclin; Elisabeth Hustert; Gabriela Bleiber; Kerry Powell Golay; Anne-Catherine Aubert; Pierre Baumann; Amalio Telenti; Reinhold Kerb
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.